ThePharmYard > Controlling Your Brand's Switch Destiny

Click here to see all VirSci Corporation titles in ThePharmYard

Pay-as-you-go medical and pharmaceutical industry information

About Us | Contact Us | Terms

Managed by NetworkPharma

Sales+Marketing

Controlling Your Brand's Switch Destiny

Written by Jack Pfister this expert paper was originally published in Pharma Marketing News, Vol 3 No 1.

Product Details - See below for further product information
Note the document you buy is licensed for your own use only.

File type and size: PDF 0.225 MB
Publication size: 3 pages
Publication date: January 2004
Published by: VirSci Corporation
ThePharmYard product code: vsc019

Our Price: £5.35
You are buying an e-document. This is a digital product and therefore UK VAT @ 17.50 % will be added at Checkout if your billing address is in the EU.

Related Products:

The rigours of regulatory approval: Successfully navigating a pharmaceutical brand name through the global regulatory environment

Further Product Information

ABSTRACT

A shifting, global regulatory environment, complex consumer behavior, and unpredictable competitive response all contribute to the complexity of the Rx to OTC switch decision.

An effective strategy for maximizing the profitability of a switch begins prior to even Rx approval. The optimal timing of the actual switch may not always coincide with the end of patent protection, bottoming Rx sales, or loss of competitive advantage. Multivariate models are now available to help pharmaceutical marketers develop more preemptive strategies for switching.

The consensus among attendees at the Institute for International Research's recent RX to OTC Switch Marketers Forum-held November 19-21, 2003, in Philadelphia, PA-was that FDA Commissioner Mark McClellan is bringing a new emphasis on societal economics to the FDA, which has pharmaceutical marketers re-thinking their OTC switch strategies. According to Senior Associate Commissioner Jeff Weber, as reported in the February 10, 2003 edition of the Tan Sheet, McClellan has targeted the FDA's budgeting goals to anticipate an average increase of 50% for Rx-to-OTC switches.

The article:

reviews the economic pressures in the US and Europe that drive earlier switching strategies,

suggests when the appropriate time during a product's life cycle switching should be considered,

describes a Switch Evaluation Tool - a multivariate model - designed to help marketers compare the timing requirements and financial merits of various switch strategies, and

proposes ways that companies can start shifting the paradigm from risk to opportunity

Strategic Medcomms Forum 2010:
Reshaping the healthcare conversation

30 September 2010

Oxford University Museum of Natural History, Oxford, UK

Learn more here

What we do

ThePharmYard sells information relevant to the medical and pharmaceutical industries, on behalf of independent publishers, in the form of e-documents. Buy online now and access the information immediately.

If you have any problems or questions or comments of any sort, then do please contact us directly.

All transactions conducted independently by WorldPay

basket

checkout

terms

Browse all publications in ThePharmYard from VirSci Corporation.

Selected Special Offers

1. Venlafaxine in Depression (in Primary Care)

2. Tiotropium in COPD (in Primary Care)

3. Pravastatin in Lipid Disorders (in Primary Care)

4. Escitalopram in Depression (in Primary Care)

5. Nicorandil in Angina (in Primary Care)

Our Best Sellers

1. An overview of CME/CPD credit systems around the world

2. Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications

3. Stepping up to Medical Sales Success - 2nd Edition

4. Quid Pro Quo Deals

5. Bipolar disorder - Disease overview

6. Bipolar disorder - Improving Practice (UK)

7. Olanzapine in bipolar disorder - Drug review

8. Developing Win-Win Key Opinion Leader Relationships

9. Levocetirizine in Allergic Rhinitis (in Primary Care)

10. Customer-Driven Positioning: The next generation approach to pharmaceutical product positioning

Latest Additions

1. Future of European Pharmaceutical Distribution

2. Global Dental Implants Market (2010 -2015)

3. Discretion is the better part of value: Five research-based rules for ensuring that strategy implementers implement

4. The competitive environment and hospital performance: An empirical investigation

5. Antecedents, environmental moderators and consequences of market orientation: A study of pharmaceutical firms in Ghana

Need help?

If you can't find what you are looking for, or have any problems or questions or comments at all, then please contact us directly.

If you are an Author or Publisher and have one or more publications you would like to make available to our specialist medical and pharmaceutical industry audience, then please contact us directly.

If you run your own web site and want to earn money from our affiliate scheme then please contact us directly.

Affiliates | About Us | Contact Us | Terms

ThePharmYard is an initiative for the international medical and pharmaceutical industries from NetworkPharma Ltd. Copyright 2010

Other services managed by NetworkPharma: [www.EuropeanCMEforum.eu] [www.KeywordPharma.com] [www.MedCommsForum.com] [www.MedCommsNetworking.co.uk] [www.NetworkPharma.tv] [www.ThePublicationPlan.com]

We accept the following credit and debit cards: amex visa visa_delta visa_electron mastercard switch jcb solo